Aravive Investor Presentation Deck

Batiraxcept Phase 3 Registrational Trial Design in PROC (Clinical Trials.gov NCT04729608) FDA Feedback: If positive, trial could support full approval in PROC; no further preclinical or clinical studies required for BLA at this time Endpoint Assessment: PFS per RECIST V1.1; radiological imaging every 8 weeks N of 350 Key Eligibility Criteria High-grade serous ovarian cancer pathology 1-4 prior lines ECOG 0-1 i i . Stratifications: Prior bevacizumab use Lines of therapy Platinum-free interval Batiraxcept + PAC 1:1 Randomization Dosing: Batiraxcept 15 mg/kg q 2 weeks + paclitaxel for 3 weeks, followed by 1 week off versus paclitaxel alone every week for 3 weeks, followed by 1 week off Placebo + PAC Endpoints + Hierarchical Endpoints: 1. PFS in the bevacizumab naïve2 population PFS in the total population 2. . OS is secondary endpoint Readout expected in mid 2023 . BLA submission anticipated near end of 2023 * Selection of patient population and dose in this trial confirmed by an IST showing lack of benefit outside this patient population and dose of 15mg/kg batiraxcept 2 Naive defined as patients who are medically ineligible to receive bevacizumab or who chose not to receive bevacizumab ECOG = Eastern Cooperative Oncology Group (ECOG) Performance Status, PFS-progression-free survival, BLA= biologics license application 19

View entire presentation